Forbes February 23, 2025
A mRNA-based cancer vaccine has shown impressive results in a small trial in patients with pancreatic cancer, showing that the vaccine can stimulate a long-term immune response that reduces the risk of cancer recurrence after surgery.
New results from the phase I clinical trial testing mRNA vaccine autogene cevumeran were published in the journal Nature. They show that the mRNA vaccines, in combination with another type of immunotherapy called an immune checkpoint inhibitor stimulated an immune response against proteins found on the tumor. These immune cells were detected in trial...
Today's Sponsors
Today's Sponsor